Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/36945
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Awada, Ahmad | - |
dc.contributor.author | Berghmans, Thierry | - |
dc.contributor.author | Clement, Paul M. | - |
dc.contributor.author | CUPPENS, Kristof | - |
dc.contributor.author | De Wilde, Bram | - |
dc.contributor.author | Machiels, Jean-Pascal | - |
dc.contributor.author | Pauwels , Patrick | - |
dc.contributor.author | Peeters , Marc | - |
dc.contributor.author | Rottey, Sylvie | - |
dc.contributor.author | Van Cutsem , Eric | - |
dc.date.accessioned | 2022-03-21T10:46:32Z | - |
dc.date.available | 2022-03-21T10:46:32Z | - |
dc.date.issued | 2022 | - |
dc.date.submitted | 2022-03-18T09:50:54Z | - |
dc.identifier.citation | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 169 (Art N° 103564) | - |
dc.identifier.uri | http://hdl.handle.net/1942/36945 | - |
dc.description.abstract | Fusions of NTRK (neurotrophic tyrosine receptor kinase) genes with 5' partner genes can result in the expression of chimeric proteins that drive oncogenesis through ligand-independent kinase activation. Despite variable frequencies of NTRK fusions in different tumor types, the fact that they are common to a wide range of cancers raises the possibility of developing tumor-agnostic treatments specifically targeting NTRK fusion products, irrespective of tumor type. The first-generation Trk (tropomyosin receptor kinase) inhibitor, larotrectinib, was the first tumor-agnostic treatment of NTRK fusion-positive cancers in adults and children, to be approved in the European Union. This consensus, developed by a Belgian multidisciplinary expert panel, aims to highlight the unmet medical need associated to NTRK fusion-driven cancer treatment and, based on current knowledge of NTRK fusions and larotrectinib treatment outcome and safety, provide comprehensive guidance to oncologists regarding NTRK fusion-driven cancer diagnostics and the best use of larotrectinib in real-world clinical settings. | - |
dc.description.sponsorship | We wish to thank the Modis platform for editorial assistance and manuscript coordination, on behalf of Bayer. Marc Pirson provided medical writing support and Pauline De Berdt coordinated manuscript development. | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.rights | 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license | - |
dc.subject.other | Larotrectinib | - |
dc.subject.other | NTRK gene fusion | - |
dc.subject.other | Trk inhibitor | - |
dc.subject.other | Tumor-agnostic | - |
dc.subject.other | Expert opinion | - |
dc.subject.other | Oncogene proteins | - |
dc.subject.other | Protein kinase inhibitors | - |
dc.title | Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib | - |
dc.type | Journal Contribution | - |
dc.identifier.volume | 169 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | Awada, A (corresponding author), Univ Libre Bruxelles, Jules Bordet Inst, Oncol Med Dept, Rue Heger Bordetstr 1, Brussels, Belgium. | - |
dc.description.notes | ahmad.awada@bordet.be | - |
local.publisher.place | STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA | - |
local.type.refereed | Refereed | - |
local.type.specified | Review | - |
local.bibliographicCitation.artnr | 103564 | - |
dc.identifier.doi | 10.1016/j.critrevonc.2021.103564 | - |
dc.identifier.isi | WOS:000760448600013 | - |
dc.contributor.orcid | Cuppens, Kristof/0000-0002-8153-0008; De Wilde, Bram/0000-0003-0213-1322 | - |
local.provider.type | wosris | - |
local.description.affiliation | [Awada, Ahmad] Univ Libre Bruxelles, Jules Bordet Inst, Oncol Med Dept, Rue Heger Bordetstr 1, Brussels, Belgium. | - |
local.description.affiliation | [Berghmans, Thierry] Univ Libre Bruxelles, Inst Jules Bordet, Thorac Oncol Clin, Brussels, Belgium. | - |
local.description.affiliation | [Clement, Paul M.] Katholieke Univ Leuven, Dept Oncol, Leuven Canc Inst, Leuven, Belgium. | - |
local.description.affiliation | [Cuppens, Kristof] Jessa Hosp, Dept Pulmonol & Thorac Oncol, Hasselt, Belgium. | - |
local.description.affiliation | [De Wilde, Bram] Ghent Univ Hosp, Dept Pediat Hematol Oncol & Stem Cell Transplanta, Ghent, Belgium. | - |
local.description.affiliation | [Machiels, Jean-Pascal] Catholic Univ Louvain, Clin Univ St Luc, Dept Med Oncol, Inst Roi Albert 2, Brussels, Belgium. | - |
local.description.affiliation | [Machiels, Jean-Pascal] Catholic Univ Louvain, Clin Univ St Luc, Inst Rech Clin & Expt POLE MIRO, Brussels, Belgium. | - |
local.description.affiliation | [Pauwels, Patrick] Univ Hosp Antwerp, Dept Pathol, Edegem, Belgium. | - |
local.description.affiliation | [Peeters, Marc] Multidisciplinary Oncol Ctr Antwerp UZA, MIPRO UA, B-2650 Edegem, Belgium. | - |
local.description.affiliation | [Rottey, Sylvie] Univ Hosp Ghent, Dept Med Oncol, Ghent, Belgium. | - |
local.description.affiliation | [Van Cutsem, Eric] Univ Leuven, Univ Hosp Gasthuisberg, Dept Digest Oncol, Leuven, Belgium. | - |
local.uhasselt.international | yes | - |
item.fullcitation | Awada, Ahmad; Berghmans, Thierry; Clement, Paul M.; CUPPENS, Kristof; De Wilde, Bram; Machiels, Jean-Pascal; Pauwels , Patrick; Peeters , Marc; Rottey, Sylvie & Van Cutsem , Eric (2022) Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib. In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 169 (Art N° 103564). | - |
item.accessRights | Open Access | - |
item.fulltext | With Fulltext | - |
item.contributor | Awada, Ahmad | - |
item.contributor | Berghmans, Thierry | - |
item.contributor | Clement, Paul M. | - |
item.contributor | CUPPENS, Kristof | - |
item.contributor | De Wilde, Bram | - |
item.contributor | Machiels, Jean-Pascal | - |
item.contributor | Pauwels , Patrick | - |
item.contributor | Peeters , Marc | - |
item.contributor | Rottey, Sylvie | - |
item.contributor | Van Cutsem , Eric | - |
crisitem.journal.issn | 1040-8428 | - |
crisitem.journal.eissn | 1879-0461 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib _ Elsevier Enhanced Reader.pdf | Published version | 4.65 MB | Adobe PDF | View/Open |
WEB OF SCIENCETM
Citations
11
checked on Oct 6, 2024
Page view(s)
22
checked on Sep 7, 2022
Download(s)
8
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.